Vagus nerve stimulation (VNS) has long been recognized for its capacity to mitigate pain and modulate mood, yet the precise neural circuits underlying these effects have remained largely obscure. A groundbreaking study from Tang, Shao, Luo, and colleagues, published in Nature Neuroscience in 2026, has now illuminated a novel brainstem pathway crucial for the integration of somatic pain signals and the subsequent modulation of negative affect by VNS. Their work identifies a distinct population of neurons in the caudal nucleus of the solitary tract (cNTS) projecting to the periaqueductal gray (PAG), providing fresh insights into the neurobiological underpinnings of VNS-mediated analgesia.

The cNTS plays a pivotal role within the brainstem, acting as a hub where visceral afferents conveyed by the vagus nerve converge alongside somatic sensory inputs. However, discerning how this region translates nociceptive stimuli into behavioral and affective responses has posed a formidable challenge. The study’s authors pinpointed a specific subset of neurons within the cNTS, herein referred to as cNTS^PAG neurons, that project directly to the PAG, a midbrain structure critically involved in descending pain modulation.

Utilizing cutting-edge optogenetic tools, the researchers selectively activated cNTS^PAG neurons in mice, which resulted in behaviors indicative of pain and discomfort. This causative link not only underscores the functional relevance of this brainstem circuit but also mirrors the phenotypes typically alleviated by VNS, strengthening the conceptual framework that these neurons serve as a conduit between peripheral pain signaling and central modulation.

Intriguingly, cNTS^PAG neurons demonstrated a remarkable specificity in encoding pain modalities. When subjected to mechanical stimuli, these neurons exhibited robust firing patterns distinct from those evoked by thermal stimuli, implicating a nuanced sensory discrimination capability. Beyond mere sensory encoding, the neuronal activity was shown to carry predictive signals after associative learning, suggesting that the cNTS^PAG circuit is also involved in the anticipation of pain and potentially in the modulation of affective states linked to pain memory.

To further dissect the role of sensory inputs, the team employed targeted inhibition techniques focused specifically on spinal inputs converging onto cNTS^PAG neurons. This intervention led to a selective diminution of mechanical nociception without markedly affecting thermal pain responses. This differential outcome highlights a modality-specific gating mechanism operational within the cNTS^PAG pathway, an insight that could reorient therapeutic strategies towards more tailored pain interventions.

Perhaps most striking is the revelation that VNS exerts its analgesic influence by selectively attenuating activity within cNTS^PAG neurons in response to pain stimuli. The stimulation recruited local inhibitory circuits within the cNTS, dampening pain-evoked excitatory neuronal activity and thereby preventing the normal transmission of nociceptive signals to the PAG. This neural inhibition manifests as a tangible reduction in pain perception and accompanying negative affect, adding depth to our understanding of VNS’s multifaceted therapeutic effects.

Complementing these neuronal findings, the study also examined downstream effects on the nucleus accumbens, a key brain region implicated in reward processing and affect. VNS was found to counteract pain-induced dopamine reductions in this area, and this effect was mediated through the cNTS^PAG pathway. The maintenance of dopaminergic tone in the face of nociceptive stimuli potentially underlies the observed alleviation of negative affect, linking the brainstem circuitry with mesolimbic reward systems in a novel framework.

This integration of visceral sensory processing, midbrain pain regulation, and dopaminergic modulation forms the basis of a new conceptual model for VNS-induced analgesia and mood improvement. The identification of cNTS^PAG neurons as a nodal element offers a promising target for precision neuromodulation therapies. Unlike broad VNS approaches, which stimulate the vagus nerve indiscriminately, future interventions may hone in on this specific pathway to maximize efficacy and minimize side effects.

The implications of these findings extend beyond pain management alone. Given the centrality of the PAG in aversive behavior and affect, and the nucleus accumbens’ role in motivation and reward, the cNTS^PAG axis may participate in a broader spectrum of neuropsychiatric phenomena. Whether modulating anxiety, depression, or stress-related disorders, this brainstem circuitry could represent a universal hub for linking somatic sensations with emotional states.

Importantly, the use of advanced methodological approaches such as optogenetics, in vivo imaging, and cell type-specific inhibition lends robustness to the conclusions drawn. These tools allow for the dissection of neural circuits with unprecedented specificity, shedding light on the unique contribution of discrete neuronal populations in complex behaviors. The study’s careful delineation of sensory modalities and learning-dependent changes in neuronal activity enriches our understanding of the dynamic nature of pain processing.

Looking ahead, this research opens several avenues for exploration. For instance, the molecular identity of the inhibitory interneurons recruited by VNS and their synaptic mechanisms remain to be defined. Additionally, examining how chronic pain conditions alter cNTS^PAG circuit function could reveal maladaptive plasticity amenable to targeted intervention. Moreover, the potential for translating these findings into clinical neuromodulation devices poised to selectively engage cNTS^PAG neurons is tantalizing.

The paradigm-shifting discovery also challenges existing dogmas about the hierarchical organization of pain processing. Rather than a unidirectional pathway flowing from periphery to cortex, the cNTS^PAG axis exemplifies a brainstem circuit capable of bidirectional modulation, integrating sensory, affective, and neuromodulatory elements. This layered complexity enriches the broader narrative of how the nervous system orchestrates adaptive responses to aversive stimuli.

In summary, the identification of a cNTS to PAG projection as a critical mediator of vagal nerve stimulation’s analgesic and affective effects marks a seminal advance in pain neuroscience. By linking peripheral nerve stimulation to central circuit dynamics and behavioural outcomes, this discovery bridges a crucial knowledge gap. It offers a mechanistic foundation for the development of precisely targeted neuromodulation therapies that could revolutionize pain management and improve quality of life for millions suffering from chronic pain syndromes worldwide.

The work by Tang and colleagues thus redefines our perspective on the neurobiology of pain and neuromodulation. It underscores the importance of brainstem nuclei, often overshadowed by cortical and limbic regions, in orchestrating complex integrative processes. With the advent of more refined neuromodulatory technologies and a growing arsenal of circuit-level tools, the era of bespoke pain therapies informed by a detailed mechanistic understanding is now within reach.

As the field moves forward, leveraging the identified cNTS^PAG circuit and its molecular and electrophysiological characteristics promises to yield unprecedented therapeutic benefits. The prospect of fine-tuning the brainstem’s intrinsic capacity to regulate pain and affect holds great promise, heralding a future where debilitating pain can be alleviated through targeted, minimally invasive neuromodulation strategies grounded in fundamental neuroscience discoveries.

---

Subject of Research: Neural circuits underlying vagal nerve stimulation (VNS)-mediated modulation of somatic pain and affective states.

Article Title: A brainstem pathway underlying vagal modulation of somatic pain and affective states.

Article References:
Tang, Y., Shao, R., Luo, L. et al. A brainstem pathway underlying vagal modulation of somatic pain and affective states. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02313-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02313-0

The European Commission (EC) took the wraps off a sweeping new package outlining measures to boost the continent’s ambitions around semiconductors, AI, cloud and open source, as part of a bid to strengthen the bloc’s digital autonomy.

EC stated measures in the four areas will help Europe “become an AI continent”, established as a leader in research, development and adoption of AI.

It hopes the package will fast track ambitions around technology sovereignty and protect European digital independence, as part of a long-standing goal to reduce reliance on the US and Asia.

Starting with chips, the EC said it wants to secure the semiconductor base for Europe’s AI ambitions through the Chips Act 2.0, which is designed to speed up permitting, deepen cooperation with “like-minded partners” and introduce a new excellence label for Europe’s semiconductor regions.

It is an update of the original Chips Act, in force since 2023, which represented Europe’s response to vulnerabilities in the semiconductor supply chain.

Secondly, a new Cloud and AI Development Act is designed to aid the buildout of new data centres, streamline conditions for deploying facilities across the European Union (EU) and introduce a single EU-wide framework to assess cloud and AI sovereignty. The wider aim is to triple the region’s data centre capacity in the next five to seven years.

Through open source, the EC wants to strengthen digital autonomy, scaling up alternatives in priority areas, invest in skills, startups and digital infrastructure while support greater use of open source in public administration.

Finally, the EC put the focus on digitalising Europe’s energy system, pledging to define a roadmap in the sector to ensure data centres are integrated, while building sovereign and secure AI models.

Technological sovereignty
Ursula von der Leyen, president of the commission, said Europe “cannot afford to depend on others for the technologies that keep our hospitals running, our energy grids stable and our services secure”.

“This is about protecting our citizens, defending our interests and making our own choices. Europe has the talent, the research excellence, the industrial base and the Single Market. Together, we must turn these strengths into technological sovereignty.”

Before the package is put into force, the proposal will be negotiated by the European Parliament and Council of the EU. The commission will also launch a consultation process with member states.

Investment will be made through existing grants until 2028, while future funding is to be confirmed in the next EU budget. The EC has previously estimated a combined public-private investment of €120 billion by 2035 to rejuvenate the continent’s chip industry.

The post EU targets AI, chips in fresh sovereignty drive appeared first on Mobile World Live.

Ofcom called for a concerted effort from mobile operators, local authorities and other entities to improve coverage across the UK, as it published a study highlighting widespread mobile signal issues uncovered on the country’s railway network.

Its research assessed coverage on 24 segments of the UK’s key railway lines. A good performance was deemed to be a download speed of at least 5 Mb/s, 1.5 Mb/s upload, and a response time of 50 milliseconds or less.

It found EE met those standards on 42% of the lines, Virgin Media O2 hit 20%, Vodafone scored 17% and 3 UK 21%. The latter two are now the same company.

Ofcom noted the research “highlights the core problem that mobile signal from masts on the ground often isn’t strong enough around train lines and that some carriage types are difficult for signals to pass through”.

It also found on-board Wi-Fi by train companies was little help, performing well 1% of the time. This was blamed on “outdated technology” and speed caps.

Goals
Alongside the train-specific research, the regulator published a report detailing general aims to improve the quality of mobile coverage in the country.

Here, Ofcom called for a “national effort” to improve services, noting the roles of the mobile industry, local authorities, central government, building developers and landowners.

Highlighting a binding £11 billion investment commitment from VodafoneThree related to merger clearance, Ofcom expects “other networks to respond with their own investment, and collectively this will be a key driver of improvements”.

Ofcom also pointed to issues with infrastructure planning applications in some areas and the advantage of having dedicated indoor coverage systems within sites such as shopping centres.

On train-specific problems, it noted “competition between mobile networks alone won’t be enough to improve mobile signal on trains, and government is currently considering options for how it can help”.

“As well as providing technical advice to Government to help inform its approach, we’ll also look at whether more spectrum – the airwaves all wireless technology relies on – is required”.

Challenges
A statement issued by trade association Mobile UK on behalf of the country’s three mobile operators welcomed the Ofcom research, explaining it “highlights the unique structural and capacity challenges of delivering consistent connectivity on moving trains”.

Noting building the advanced infrastructure required needed “the right enabling environment” the organisation urged government action through the country’s Mobile Market Review and “planning reform to establish a supportive policy and regulatory framework”.

“Dedicated public investment is also critical to tackle complex trackside blackspots, as commercial rollout alone cannot bridge the gap on the rail network,” the statement added. “We look forward to working with Government and Ofcom to achieve this, balancing the need for major investment with Ofcom’s vital role in maintaining low costs for consumers.”

The post UK regulator bemoans train mobile signal failures appeared first on Mobile World Live.

Online publishers are getting more control over whether their websites appear in Google's AI Search features, thanks to a UK regulatory ruling. The new conduct rule imposed by the Competition and Markets Authority (CMA) requires Google to let website owners keep their content out of features like AI Overviews and prevent it from being used for the "fine-tuning" of Google's AI models.

"In a world first, publishers will now have effective tools to prevent their content being used to power AI features in search, such as AI Overviews," the CMA announced. "This will put publishers, like news organizations, in a stronger position to negotiate co …

Read the full story at The Verge.

The Federal Communications Commission (FCC) opened its first spectrum auction in four years, putting 200 licences on the block for bidding by AT&T, T-Mobile US, Verizon and possibly SpaceX.

Auction 113, formally known as the AWS-3 auction, includes licences covering frequencies in the 1695–1710 MHz, 1755–1780 MHz and 2155–2180 MHz bands.

Those frequencies were originally auctioned to Dish Network, which is now part of EchoStar, in 2014 but never made it into service after a series of defaults and bid withdrawals left them sitting unused in the FCC’s inventory for over a decade.

In 2015, Dish Network affiliates Northstar Wireless and SNR Wireless surrendered a number of spectrum licences worth $3.5 billion after a dispute with the FCC over discounts.

Last week the FCC and EchoStar reached an agreement which included the latter dropping a lawsuit it filed in a US Court of Appeals over the defaults by Northstar and SNR.

Proceeds from the auction which started yesterday (2 June) will fund the FCC’s secure and trusted communications networks reimbursement program, commonly known as “rip and replace”. It seeks to remove equipment by Huawei and ZTE from US communications networks.

The licences cover territory home to more than 100 million people across 48 states, and two US territories. The auction makes over 1.4 billion MHz-POPs available.

FCC chair Brendan Carr did not hold back in marking the occasion.

“Finally! The FCC is back in the game,” he stated while calling spectrum auctions “the lifeblood of licensed wireless service”.

Carr noted getting this auction moving was the first item the FCC voted on at his first meeting as chair.

“More spectrum means more building, lower prices and stronger competition,” he added.

The auction fits into the FCC’s broader Build America Agenda, which is targeting the delivery of 800 megahertz of spectrum by 2034 under the framework set out in President Donald Trump’s Working Families Tax Cut Act, the legislation which also restored the FCC’s auction authority.

The post FCC kicks off first spectrum auction in 4 years appeared first on Mobile World Live.

In a groundbreaking study poised to reshape therapeutic strategies for lung adenocarcinoma, researchers have uncovered a pivotal mechanism by which the transcription factor MYBL2 diminishes the efficacy of cisplatin chemotherapy. The study, led by Lu, Zhang, Xuzhang, and colleagues, elucidates how MYBL2 suppresses GSDME-mediated pyroptosis, a form of programmed cell death known to enhance the anti-cancer effects of chemotherapy. This novel insight, published in Cell Death Discovery, highlights the intricate interplay between oncogenic regulators and cell death pathways, offering new avenues for overcoming drug resistance in one of the most lethal forms of lung cancer.

Lung adenocarcinoma remains a formidable clinical challenge, being the most common histological subtype of non-small cell lung cancer (NSCLC). Cisplatin-based chemotherapy regimens are front-line treatments, yet their effectiveness is severely hindered by the emergence of resistance mechanisms. While traditional models have focused on apoptotic evasion, the discovery that pyroptosis—a highly inflammatory and lytic form of cell death—plays a critical role in mediating chemotherapy sensitivity has invigorated the field. Pyroptosis is executed chiefly through the action of gasdermin proteins, with GSDME garnering significant attention for its tumor-suppressive functions.

The research team embarked on an in-depth molecular investigation to decipher the relationship between MYBL2 and GSDME in lung adenocarcinoma cells subjected to cisplatin treatment. MYBL2, known as a regulator of cell cycle progression and proliferation, has been reported to be overexpressed in various cancers, correlating with poor prognosis and aggressive phenotypes. By employing a combination of genetic manipulation, transcriptomic analysis, and functional assays, the study provides compelling evidence that elevated MYBL2 expression results in the downregulation of GSDME-mediated pyroptosis, thereby enhancing cellular survival post-chemotherapy.

One of the key revelations of the study is the mechanistic insight into how MYBL2 suppresses pyroptosis. The researchers demonstrate that MYBL2 binds to the promoter regions of the GSDME gene and represses its transcriptional activation. This epigenetic modulation effectively reduces the cellular pool of GSDME, impairing the cleavage events necessary for pyroptotic execution. Consequently, lung adenocarcinoma cells with high MYBL2 expression exhibit a marked resistance to cisplatin-induced pyroptosis and maintain proliferative capacity despite cytotoxic stress.

Beyond transcriptional repression, the study further explores the downstream signaling cascades that intertwine with MYBL2 activity. Intriguingly, the data reveal that MYBL2 expression modulates the balance between apoptotic and pyroptotic pathways in a context-dependent manner. The attenuation of pyroptosis not only limits the direct killing of tumor cells but also reduces the immunogenic potential of chemotherapy. Pyroptotic cell death serves to release pro-inflammatory signals that activate immune surveillance mechanisms; thus, MYBL2-mediated suppression may contribute to an immunosuppressive tumor microenvironment.

This dual role of MYBL2 underscores its potential as a therapeutic target. The researchers propose that pharmacological or genetic inhibition of MYBL2 might restore GSDME expression and pyroptotic responsiveness, sensitizing tumors to cisplatin. Such approaches could synergize with immunotherapies, given the heightened antigen presentation and immune activation following pyroptotic cell death. Indeed, preclinical models assessing MYBL2 knockdown demonstrated increased cisplatin sensitivity and augmented immune cell infiltration, lending credence to this therapeutic strategy.

The findings also invite a re-examination of resistance paradigms in lung adenocarcinoma. Traditional studies have predominantly centered on apoptosis evasion, but this work broadens the perspective by incorporating pyroptosis as a critical determinant of chemotherapeutic outcome. The suppression of GSDME-mediated pyroptosis emerges as a previously underappreciated axis of resistance, revealing vulnerabilities that could be exploited for improved patient prognosis.

Technologically, the study utilized cutting-edge next-generation sequencing to profile transcriptomic changes associated with MYBL2 modulation. Chromatin immunoprecipitation assays provided fine-scale mapping of MYBL2 binding sites, confirming direct regulation of GSDME. Functional assays, including lactate dehydrogenase release and caspase-3 activation studies, substantiated the pyroptotic phenotype and its alteration by MYBL2. This comprehensive methodological framework validates the robustness of the findings and sets a new standard for mechanistic oncology research.

Importantly, the clinical implications of MYBL2 expression levels were examined across patient tumor samples. Higher MYBL2 correlated with diminished GSDME expression and poorer responses to cisplatin. This correlation not only serves as a prognostic biomarker but also offers a stratification strategy for personalized medicine. Patients exhibiting high MYBL2 may benefit from combination regimens aiming to restore pyroptosis or bypass MYBL2-driven blocks.

The researchers also ventured into potential feedback loops and compensatory mechanisms activated in response to MYBL2 inhibition. Early data suggest that while MYBL2 is a master regulator, tumor cells may engage alternative pathways to evade pyroptosis. This underscores the complexity of therapeutic targeting and the necessity for combination treatments addressing multiple facets of cell death resistance.

From a broader perspective, this study enriches our understanding of the functional diversity of gasdermin family members in cancer biology. Whereas GSDME has been under exploration, linking its activity explicitly to chemotherapy sensitivity through modulation by transcription factors such as MYBL2 is a paradigm shift. It raises questions about the interplay of other oncogenes and tumor suppressors in regulating pyroptosis and other non-apoptotic cell death programs.

Future research spurred by these findings will likely focus on the development of MYBL2 inhibitors or modulators capable of reinstating pyroptotic death in cancer cells. The challenge will be to achieve specificity, minimizing off-target effects given MYBL2’s role in normal cellular processes. Additionally, evaluating combinatory treatments incorporating immune checkpoint blockade, epigenetic drugs, and pyroptosis inducers could revolutionize lung adenocarcinoma therapy.

In conclusion, the study by Lu et al. marks a significant advance in the molecular oncology field by delineating how MYBL2 curtails the chemotherapeutic potential of cisplatin through suppression of GSDME-driven pyroptosis. These insights pave the way for innovative interventions targeting resistance mechanisms at the level of cell death regulation and immune engagement, ultimately aiming to improve survival outcomes for patients facing lung adenocarcinoma.

---

Subject of Research: Mechanisms of cisplatin resistance in lung adenocarcinoma via MYBL2 regulation of GSDME-mediated pyroptosis.

Article Title: MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.

Article References:
Lu, T., Zhang, J., Xuzhang, W. et al. MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03175-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03175-y

In the intricate world of cellular biology, caveolae have long captured the curiosity of researchers due to their unique structure and multifaceted roles within the plasma membrane. These diminutive, cup-shaped invaginations, laden with caveolin and cavin proteins alongside cholesterol and glycosphingolipids, constitute specialized nanodomains that are increasingly recognized as pivotal regulators of cellular behavior. Recent groundbreaking studies, leveraging ultra-advanced imaging technologies such as super-resolution fluorescence microscopy and high-resolution cryo-electron microscopy, have unveiled unprecedented insights into the structural and dynamic complexity of caveolae, revolutionizing our understanding of their function and impact.

These structural studies have illuminated the exquisite molecular architecture of caveolae, revealing caveolin oligomers as fundamental scaffolding components that not only shape the plasma membrane but also orchestrate dynamic responses to environmental stimuli. The resting state of caveolae embodies a metastable equilibrium, delicately balanced to enable immediate and controlled disassembly. This rapid structural plasticity is critical, allowing caveolae to swiftly react to mechanical forces and biochemical signals, thus maintaining cellular homeostasis and responsiveness.

Delving deeper into their physiological relevance, caveolae emerge as central mechanosensors and mechanotransducers, pivotal in transducing mechanical cues into biochemical signals. Endothelial cells exploit caveolae to finely tune nitric oxide signaling pathways and facilitate selective substrate transcytosis, processes essential for vascular function and immune surveillance. Meanwhile, in metabolically active tissues like adipocytes and myocytes, caveolae are integral to lipid metabolism and confer resilience against mechanical stress, thereby safeguarding membrane integrity under fluctuating mechanical loads.

The capacity of caveolae to sense and respond to mechanical stress constitutes an elegant cellular buffer against mechanical perturbations, a feature that ensures membrane stabilization during events such as shear stress, stretch, or osmotic swelling. This mechanoprotection relies on caveolae’s ability to flatten out and increase the plasma membrane surface area transiently, thus mitigating membrane tension surges. This phenomenon represents a sophisticated cellular strategy, shielding critical signaling platforms and membrane domains from mechanical damage, while maintaining signaling fidelity.

Equally compelling is the role of caveolae in orchestrating mechanotransduction pathways that influence fundamental cellular processes including proliferation, migration, and differentiation. Their interplay with the cytoskeleton and lipid microdomains places caveolae at a nexus of biochemical cascades triggered by mechanical stimuli, influencing gene expression patterns and cellular phenotype adaptations. This mechanosensitive capacity underscores the importance of caveolae beyond structural maintenance, positioning them as active players in cell-environment communication.

However, it is the burgeoning link between caveolae dysfunction and human diseases that has galvanized scientific and medical interest. Aberrations in caveolae mechanics—often stemming from mutated caveolin or cavin proteins—have been implicated in a spectrum of pathologies ranging from cardiovascular diseases, metabolic syndromes, to cancer progression and muscular dystrophies. Specifically, impaired caveolae mechanosensitivity compromises endothelial barrier function, disrupts lipid metabolic networks, and diminishes cellular mechanical robustness, cumulatively precipitating disease phenotypes.

These revelations advocate for a paradigm shift in therapeutic strategies, motivating efforts to target caveolae or their constituent proteins to restore cellular mechanoprotection and signaling equilibrium. Pharmacological modulation aimed at stabilizing caveolae structures or enhancing their mechanosensitive capabilities may open new avenues for treating conditions associated with caveolae impairment. Moreover, caveolae components could serve as valuable biomarkers for early disease detection or progression monitoring.

From a biophysical standpoint, the metastable architecture of caveolae exemplifies a remarkable evolutionary adaptation—balancing membrane flexibility with functional specificity through intricate protein-lipid assemblies. This fine-tuned equilibrium enables cells not only to withstand variable mechanical environments but also to translate these physical forces into meaningful biochemical responses. Ongoing research employing cutting-edge cryo-EM and nanoscale imaging continues to unravel the precise molecular mechanisms underpinning this functional versatility.

Moreover, integrating systems biology approaches has provided a holistic perspective on caveolae dynamics, revealing how these nanodomains participate in broader cellular signaling networks and interact with other mechanosensitive organelles. Such integration underscores the complexity of intracellular communication and the centrality of caveolae in maintaining cellular and tissue homeostasis under mechanical stress.

In parallel, advances in synthetic biology are beginning to harness caveolae-inspired designs to engineer mechanosensitive artificial membranes and nanoscale sensors. These biomimetic platforms hold promise not only in elucidating fundamental caveolae mechanics but also in developing novel diagnostic tools and therapeutic delivery systems that respond to mechanical cues within the human body.

On the frontier of cellular mechanobiology, caveolae continue to exemplify the sophistication of nano-scale cellular architectures that integrate structural, mechanical, and signaling functions. Their study not only deepens fundamental biological knowledge but also informs translational applications, bridging the gap between basic science and clinical innovation. As technologies evolve, our capacity to decode and manipulate caveolae mechanics promises to reveal new dimensions of cellular function and disease modulation.

In conclusion, the past decade has witnessed transformative advancements in caveolae research, propelled by technical innovations that capture their elusive structure and rapid dynamics in action. The elucidation of caveolae’s mechanosensitive properties and their critical roles in cellular physiology and pathology positions these nanodomains as vital components of the cellular machinery. Continued exploration holds immense potential to drive forward next-generation biomedical interventions that harness or rectify caveolae mechanics for therapeutic benefit.

Subject of Research: Caveolae mechanics, cellular mechanosensing, and the role of caveolin/cavin proteins in membrane homeostasis and disease.

Article Title: Caveolae mechanics in cellular functions and disease.

Article References:
Lamaze, C., Blouin, C.M. & Sens, P. Caveolae mechanics in cellular functions and disease. Nat Rev Mol Cell Biol (2026). https://doi.org/10.1038/s41580-026-00964-2

Image Credits: AI Generated

DOI: 10.1038/s41580-026-00964-2

Keywords: Caveolae, caveolin, cavin, mechanosensing, membranes, mechanotransduction, lipid homeostasis, mechanoprotection, cryo-electron microscopy, super-resolution microscopy.

In an unprecedented exploration into the dynamic interplay between microbiota and host physiology, a groundbreaking study has illuminated the pivotal role of microbial enzymes in modulating gut motility through reactivation of host androgens. Published in Nature Neuroscience in 2026, this research uncovers how microbial metabolism intricately directs enteric neuronal circuits, reshaping our understanding of the gut-brain axis with profound implications for human health and disease.

The study embarks from the well-documented influence of androgens—steroid hormones traditionally associated with male traits—on various physiological systems. While systemic androgen effects have been explored, this investigation probes deeper into localized reactivation mechanisms within the gut environment, where microbial communities reside densely. Researchers reveal that resident gut microbes possess enzymatic functions capable of converting androgen precursors back into their active forms, effectively reawakening hormonal signaling within the enteric nervous system.

Employing a sophisticated combination of metabolomic profiling, genetic manipulation, and electrophysiological techniques, the team identified key bacterial taxa responsible for this enzymatic reactivation. Notably, these microbial metabolic activities were found to significantly enhance the bioavailability of active androgens in the gut lumen, directly influencing neuronal excitability and, consequently, gut motility patterns. This discovery bridges a vital gap between microbiome functionality and neuroendocrine regulation that had remained elusive until now.

Central to the findings is the concept that androgen reactivation by microbial enzymes fine-tunes enteric neuronal output, orchestrating peristaltic reflexes and smooth muscle contractions essential for intestinal transit. Through targeted in vivo experiments, the researchers demonstrated that disruption of this microbial androgen metabolism altered gut motility, resulting in either hypo- or hypermotility phenotypes. These effects were reversible upon restoration of the microbial enzymatic activity, suggesting a highly dynamic and plastic system governed by host-microbiome feedback loops.

Beyond the immediate mechanistic insights, this study challenges conventional paradigms by positioning gut microbes as active endocrine modulators rather than passive inhabitants. The realization that microbial metabolism can recalibrate host hormonal circuits highlights novel avenues for therapeutic intervention in gastrointestinal disorders characterized by dysmotility, such as irritable bowel syndrome and chronic constipation. Modulating microbial androgen reactivation could become a precision medicine strategy tailored to restore normal gut function.

Intriguingly, the researchers also unveiled sexually dimorphic responses in the interplay between microbial androgen reactivation and enteric neuron function. Male and female mice exhibited distinct motility patterns contingent upon variations in microbial enzymatic profiles and host androgen sensitivity, underscoring the importance of considering sex as a biological variable in gut-neuroendocrine research. This facet deepens our appreciation of individualized host-microbe interactions shaping health outcomes.

At the molecular level, the study elaborates on how microbial enzymes such as hydroxysteroid dehydrogenases catalyze reversible conversions between inactive androgen conjugates and their active counterparts. These enzymatic reactions take place in close proximity to enteric neurons, facilitating paracrine signaling that modulates neuronal firing rates and neurotransmitter release. This finely tuned mechanism enables the microbiome to exert sophisticated control over gut motility beyond mere metabolite production.

Furthermore, the research integrates advanced imaging modalities to visualize neuronal activity in real-time, correlating enhanced androgen availability with increased calcium fluxes and action potential frequency within enteric ganglia. This real-time functional evidence solidifies the link between microbial metabolic activity and neurophysiological outputs, offering a multi-dimensional perspective of gut regulatory networks. The convergence of metabolic and neuronal data lends robust credibility to the proposed model.

From an evolutionary standpoint, the elucidation of microbial androgen reactivation mechanisms hints at a co-evolved symbiotic relationship where microbes contribute to optimizing host intestinal function. This evolutionary insight expands the framework of mutualism, suggesting that microbiota-derived modulation of hormone signaling constitutes an adaptive advantage for maintaining digestive efficiency. Such findings provide fertile ground for evolutionary biology and microbiome research intersections.

The translational potential of these discoveries is immense. By identifying specific microbial enzyme targets, pharmaceutical development can aim to design modulators or probiotics that enhance or inhibit androgen reactivation within the gut, thereby controlling motility disorders. Moreover, these microbial pathways might influence systemic endocrine functions given the interconnectivity between enteric neurons and central nervous system circuits, opening exciting possibilities for neurogastroenterology.

Intricately, the study also discusses the feedback mechanisms wherein host androgens modulate microbial community composition and metabolic activity, establishing a bidirectional communication loop. This dynamic feedback ensures homeostasis by synchronizing microbial function with host hormonal status, representing an elegant biological system integrating metabolic, neuronal, and microbial domains. Such complexity underscores the need for holistic approaches in future gut-brain axis investigations.

Given the widespread prevalence of gut motility disorders, the identification of microbial androgen reactivation as a key regulatory mechanism invites renewed scrutiny of microbiome-targeted therapies. Dietary interventions, antibiotics, and microbiota transplants could inadvertently perturb these enzymatic activities, altering gut function. Therefore, medical practices may need to incorporate microbiome endocrine considerations to optimize patient outcomes and minimize adverse effects.

In conclusion, this seminal study redefines the microbial contribution to host physiology by unveiling a novel enzymatic process through which gut bacteria reactivate androgens, orchestrating enteric neuronal regulation of motility. This intricate biochemical crosstalk exemplifies the emerging frontier of microbiome-endocrine interactions with vast implications for biology, medicine, and therapeutics. As we unravel these complex dialogues, the prospect of leveraging microbial endocrinology to modulate health becomes an exciting reality.

The transformative insights gained here invite a paradigm shift: the gut microbiome is not merely a metabolic organ but an endocrine entity capable of recalibrating host neurophysiological processes. This revelation paves the way for integrative research endeavors bridging microbiology, endocrinology, neuroscience, and clinical medicine, ultimately advancing personalized healthcare in gastrointestinal and systemic diseases. Such interdisciplinary synergy heralds a new epoch of microbiome-informed biomedical breakthroughs.

As the field advances, further studies will doubtless explore how microbial androgen reactivation interfaces with other hormonal axes and systemic immunity, deepening our comprehension of host-microbiome symbiosis. The interplay between microbial enzymatic activities and host signaling cascades likely extends beyond gut motility, influencing metabolism, mood, and behavior. The future of human health hinges upon decoding these microbial endocrine networks and harnessing their potential.

---

Subject of Research: Microbial enzymatic reactivation of host androgens and their role in enteric neuronal regulation of gut motility.

Article Title: Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility.

Article References:
Lagomarsino, V.N., Robinson, A., Mitchell, P.E. et al. Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02321-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02321-0

In the intricate dance of life’s blueprint, DNA has long been celebrated as the master code guiding organismal development and heredity. Yet, the regulation of gene activity—how genes switch on and off with exquisite precision across different cellular contexts and environmental cues—extends beyond the mere sequence of nucleotides. This regulation hinges on a complex layer of control known as epigenetics. Epigenetics encompasses chemical modifications of DNA and histone proteins that influence gene expression without altering the underlying genetic code. Among these modifications, DNA methylation, the addition of methyl groups to cytosine bases within the genome, has emerged as a pivotal mechanism modulating gene activity.

In vertebrates such as mammals, a robust epigenetic “resetting” occurs shortly after fertilization. This sweeping reprogramming strips away most inherited methylation marks, effectively erasing epigenetic memories acquired during the parents’ lifetimes and thus safeguarding embryonic development from potentially deleterious epimutations. However, this epigenetic reprogramming does not appear universal across the animal kingdom. In numerous invertebrates, including marine organisms like corals, worms, sea anemones, and sea urchins, this global erasure seems conspicuously absent, hinting at fundamental evolutionary divergences in epigenetic regulation.

A groundbreaking study recently explored these differences by experimentally disrupting DNA methylation in the starlet sea anemone, Nematostella vectensis, a cnidarian species that occupies a key phylogenetic position near the base of animal evolution. By selectively removing methylation marks within its genome, researchers sought to unravel methylation’s functional importance in an organism where typical epigenetic resetting is missing. Contrary to expectations, the anemones developed normally, even in the near complete absence of DNA methylation. This surprising resilience suggested that DNA methylation’s primary role might not be to orchestrate gene expression as traditionally envisioned.

Rather than broadly compromising gene regulation, the loss of methylation predominantly unleashed the activity of transposable elements—often referred to as “jumping genes” or selfish DNA sequences—that reside within actively transcribed genes. These genetic elements possess the capacity to move within the genome, potentially inserting themselves into critical coding or regulatory regions. If not tightly suppressed, such mobilization can disrupt gene function, precipitate genomic instability, and impair normal development. The discovery that methylation chiefly acts to restrain these disruptive elements underscores an ancestral genomic defense mechanism preserved across evolutionary epochs.

Dr. Alex de Mendoza, a leading expert in evolutionary epigenomics at Queen Mary University of London, highlighted the profound implications of these findings. Because invertebrate species like sea anemones lack the typical epigenetic cleansing during early development, abnormal methylation patterns can persist and transmit to subsequent generations. This epigenetic inheritance modulates gene expression profiles beyond what genetic code alone dictates, revealing an additional layer of heritable biological information. Such phenomena demonstrate how experimentally introduced epigenetic variation can traverse generational boundaries in animals, challenging the long-held tenet that only DNA sequence changes are heritable.

Delving deeper, the research offers a novel perspective on the evolutionary trajectory of DNA methylation. Initially, this modification appears to have evolved primarily as a genomic safeguard, protecting coding sequences from the disruptive capacity of transposable elements. Over time, in mammalian lineages, this molecular machinery was co-opted and expanded to execute broader developmental regulatory roles—acting to silence one X chromosome in females and regulate complex tissue-specific gene expression programs. The study thus illuminates how molecular systems adapt and diversify, transforming ancient genomic guardians into sophisticated regulators of vertebrate biology.

Moreover, the lack of full epigenetic reprogramming in cnidarians suggests these organisms possess an inherent capacity to maintain inherited epigenetic states, providing a reservoir of variation for natural selection to act upon. Such stable transmission of epigenetic marks without underlying genetic mutation may represent an unappreciated source of phenotypic diversity and evolutionary innovation. This challenges the paradigm that heritable biological change requires DNA sequence alteration, expanding evolutionary biology’s conceptual framework to include epigenetic mechanisms in shaping organismal adaptation.

This work also emphasizes the intricate interplay between epigenetics and genome integrity. Transposable elements constitute a significant fraction of animal genomes, and their regulation is paramount to preventing genomic chaos. DNA methylation emerges as a critical regulator, keeping these elements silenced, especially within gene bodies, where their disruptive potential is highest. The failure of this epigenetic control unleashes internal genomic parasites that can jeopardize normal gene function and organismal survival.

Intriguingly, the seemingly paradoxical normal development of methylation-deficient anemones underscores redundancy and plasticity in gene regulatory networks. The absence of overt developmental defects suggests that alternative mechanisms can compensate for lost methylation-mediated repression. This resilience hints at a genome architecture finely tuned through evolution to maintain stability even when key regulatory systems falter, underscoring the robustness of biological systems.

The study not only deepens our understanding of DNA methylation’s ancestral functions but also opens avenues for exploring how epigenetic inheritance influences ecological and evolutionary dynamics in marine ecosystems. Cnidarians represent ecologically vital keystone species; thus, their capacity to pass on epigenetic traits may impact resilience and adaptation in changing oceans, with implications for biodiversity and conservation.

Beyond evolutionary insights, the research sets a foundation for new epigenetic models that integrate heritable methylation patterns with genome defense and gene regulation. It challenges researchers to reconsider the boundaries between genetic and epigenetic inheritance and to explore how ancient molecular mechanisms continue to shape life’s diversity from sea anemones to humans. This deeper comprehension may ultimately inform biomedical approaches targeting epigenetic modifications in disease and developmental biology.

In sum, this landmark investigation redefines DNA methylation’s evolutionary purpose, positing that its primordial function was genome protection rather than gene regulation per se. The delicate dance between epigenetic marks, transposable elements, and genetic regulation emerges as a foundational axis steering animal evolution and developmental fidelity. As we dive deeper into epigenomes across diverse species, the revelations from humble sea anemones remind us that evolution often innovates by repurposing age-old molecular tools in unexpected, transformative ways.

---

Subject of Research: Not applicable

Article Title: Gene body methylation suppresses intragenic transcription and permits epigenetic inheritance in a cnidarian

Web References: 10.1038/s41559-026-03090-6

Image Credits: Karmannye Chaudhary

Keywords: Evolutionary biology, epigenetics, DNA methylation, transposable elements, epigenetic inheritance, cnidarian, genome stability, gene regulation, Nematostella vectensis

In the rapidly evolving arena of synthetic biology, precise gene regulation remains both a crucial goal and formidable challenge. Bacteria, with their intricate genetic networks and vital roles in biotechnology, serve as prime targets for engineering sophisticated gene control systems. Now, a groundbreaking study published in Nature Biotechnology unveils an innovative strategy harnessing an attenuated form of Cas13d—a powerful RNA-targeting CRISPR effector—to achieve programmable, multiplexed, and orthogonal gene regulation in Escherichia coli. This advancement opens unprecedented avenues for dynamic bacterial gene control, enabling nuanced modulation of gene expression with high specificity and minimal cytotoxicity.

Traditional CRISPR systems like Cas9 have revolutionized DNA editing, yet RNA-targeting effectors such as Cas13 bring unique advantages for reversible and tunable regulation without permanent genomic alterations. However, the application of Cas13 in bacteria has encountered a significant barrier: collateral cleavage activity. Wild-type Cas13 exhibits nonspecific RNA degradation once activated, leading to cytotoxicity and growth inhibition, thus impeding its widespread use for precise transcriptional tuning in prokaryotic cells. Overcoming this limitation required a reimagination of the Cas13 protein architecture.

The researchers addressed this by adopting a rational protein engineering approach, focusing on attenuating Cas13d’s RNase activity while preserving its targeted RNA knockdown capacity. They identified and excised flexible regions within the Cas13d protein structure hypothesized to contribute to unwanted collateral cleavage. This targeted truncation yielded a spectrum of Cas13d variants with tunable enzymatic activity. Notably, these engineered Cas13d proteins maintained their ability to silence specific transcripts efficiently, yet exhibited drastically reduced cytotoxicity, as evidenced by a remarkable 2.2-fold increase in bacterial growth optical density compared to cells harboring wild-type Cas13d.

Beyond simply dampening RNase activity, this attenuated Cas13d toolkit demonstrated an exquisite level of functional versatility, modulated by subtle changes in CRISPR RNA spacer design. By introducing proximal mismatches at the 5′ end of the spacer sequences, the system enables a programmable switch among three distinct modes of gene regulation: translation inhibition, targeted degradation of polycistronic mRNAs, and CRISPR activation at the translation level via fusion to the bacterial initiation factor IF3. This modularity allows tailored control strategies for diverse applications, ranging from silencing deleterious genes to upregulating beneficial pathways.

A particularly compelling aspect of this work is the system’s capability to exert multiplexed and orthogonal regulation within polycistronic transcripts—bacterial mRNAs that encode multiple proteins in a single RNA molecule. By designing guide RNAs targeting specific genes within these operons, the researchers successfully demonstrated simultaneous and independent control of individual gene expression. This level of granularity in bacterial gene editing was previously unattainable with conventional CRISPR tools and holds immense potential for engineering complex synthetic circuits with multiple inputs and outputs.

To showcase the practical utility of this attenuated Cas13d system, the team applied it to a classic microbial biotechnology challenge: optimization of lycopene biosynthesis in E. coli. Lycopene, a valuable carotenoid with health and industrial relevance, is synthesized via a multi-enzyme metabolic pathway that requires careful balancing of enzyme levels and fluxes. Employing their refined Cas13d-based regulatory toolkit, the researchers fine-tuned essential and competing genes within this pathway dynamically. The resulting pathway rewiring not only enhanced lycopene yields significantly but also maintained cell vitality, illustrating the harmony between metabolic optimization and cell health achievable with this sophisticated regulatory platform.

The implications of this advance ripple well beyond E. coli or lycopene synthesis. The modular, tunable nature of attenuated Cas13d effectors paves the way for next-generation microbial synthetic biology applications—from bioproduction of complex molecules to living biosensors that respond rapidly to environmental cues. The reversible and multiplexed control mechanism offers a potent toolset for probing fundamental bacterial gene function and constructing synthetic circuits with unprecedented precision.

Moreover, this technology elegantly sidesteps the permanent genomic disruptions characteristic of DNA-targeting CRISPR tools. By targeting RNA transcripts post-transcriptionally, this approach enables reversible modulation of gene expression states, allowing researchers to study temporal dynamics in bacterial physiology or develop programmable microbes that can switch functionalities in response to stimuli.

The engineering of Cas13d itself involved exploiting detailed structural and functional knowledge. Flexible regions previously overlooked were pinpointed as critical determinants for collateral cleavage. This insight underscores the power of combining structural biology with synthetic biology to reimagine natural effectors as finely controllable tools rather than blunt instruments. It opens the door for similar attenuation strategies to be applied to other RNA-targeting nucleases, amplifying the toolkit available for RNA biology and biotechnology.

The use of proximal spacer mismatches to toggle between inhibition, degradation, and activation states represents a clever exploitation of CRISPR RNA–target complementarity rules. This innovation decouples RNase activity from binding affinity and allows a single engineered Cas13d protein to perform multiple regulatory roles without further protein engineering, streamlining system design and increasing flexibility.

Importantly, the orthogonal targeting within polycistronic mRNAs highlights the potential for sophisticated bacteria-wide gene regulation at the RNA level. Since many bacterial operons encode functionally linked proteins, this ability to recalibrate individual gene outputs independently provides a powerful lever to dissect and rewire bacterial gene networks with minimal disturbance to overall cellular integrity.

The improved growth performance of bacteria expressing attenuated Cas13d variants is a vital advancement for biotechnological deployment. The reduced toxicity facilitates higher cell densities and longer cultivation times, improving production scalability. This contrasts sharply with previous Cas13 systems, where collateral damage to cellular RNAs often stagnated growth and limited practical utility.

From therapeutic applications aiming to modulate microbial communities to industrial biosynthesis frameworks requiring dynamic metabolic flux control, the attenuated Cas13d toolkit stands as a versatile and impactful innovation. It bridges longstanding gaps in RNA-targeting technologies, balancing potency with biocompatibility and programmability.

In conclusion, this study represents a seminal step in realizing dynamic, multiplexed, and reversible gene control in bacteria through rational engineering of Cas13d. By attenuating collateral cleavage and introducing spacer design-based functional switching, the authors have delivered a powerful RNA regulatory toolkit poised to transform microbial synthetic biology and biotechnology. Future research will undoubtedly explore expanding this system to diverse bacterial species, integrating it with other synthetic genetic elements, and harnessing its potential for real-time cellular reprogramming.

The scientific community is certain to embrace this versatile platform, which not only enhances our capacity to engineer bacteria but also deepens our understanding of RNA biology and CRISPR functionality. As synthetic biology marches forward, such innovations redefine the frontier of microbial gene control, unlocking new possibilities from medicine to sustainable biomanufacturing.

---

Subject of Research:
Programmable, multiplexed, orthogonal gene control in bacteria using engineered, attenuated Cas13d systems.

Article Title:
Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems.

Article References:
Tong, S., Qin, Y., Sun, Y. et al. Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03160-x

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41587-026-03160-x

President Donald Trump signed an executive order Tuesday creating a "voluntary framework" for AI companies to share their frontier models with the federal government before they're released "to promote secure innovation and strengthen the cybersecurity of critical infrastructure."

The order says the US AI industry has succeeded in part "because we refuse to stifle this innovation with overly burdensome regulation," but that it also recognizes new AI capabilities come with security risks. Accordingly, it directs several federal agencies to come up with a framework to "assess the advanced cyber capabilities of AI models" before they're releas …

Read the full story at The Verge.

AI player Anthropic confidentially submitted paperwork for its proposed initial public listing ahead of rival OpenAI, while also giving the European Union’s cybersecurity body preliminary access to its Mythos AI tool.

The draft registration statement submitted to the US Securities and Exchange Commission gives the company the option to go public after the agency completes its review.

Anthropic stated the number of shares to be offered and the price have not yet been set.

News of the IPO move came the same day (1 June) Bloomberg reported Anthropic will give ENISA, the European Union’s cybersecurity agency, access to Mythos through Project Glasswing, an initiative which allows organisations to test Mythos’ capabilities before a wider release.

There are growing concerns among governments over the security implications of Mythos, which Anthropic released to some private companies in April.

Anthropic communicated the decision to the European Commission over the weekend.

EC spokesperson Thomas Regnier confirmed the development to Mobile World Live (MWL) followed several weeks of productive discussions.

 “We welcome the latest developments on potential future access,” he said. “This is the result of the Commission’s strong bilateral cooperation and engagement with Anthropic, a leading frontier AI company.”

The EC was careful to frame the moment not as a resolution but as a starting point to work with the US administration, Anthropic and additional AI companies such as OpenAI.

“This is a shared challenge, and we are intensifying our discussions with like-minded partners, including the United States,” Regnier said.

The plan is for ENISA to join Project Glasswing, the coalition Anthropic announced in April which includes Amazon, Apple, AT&T, T-Mobile US, Microsoft, Google, CrowdStrike, Nvidia and Palo Alto Networks, among others.

The post Anthropic confidentially files for IPO appeared first on Mobile World Live.

Meta Platforms reportedly acknowledged its controversial employee surveillance programme captures data from employees outside the US, raising fresh legal questions in Europe.

Reuters reported internal documentation it reviewed showed the company’s Model Capability Initiative (MCI) does capture data outside of the US.

MCI was introduced last month as a tool to record how US-based employees interact with their work computers by tracking mouse movements, clicks and navigation patterns across more than 200 apps and websites.

The goal of MCI is to use the employee-generated data to train AI agents capable of performing coding and white-collar tasks.

Meta told staff the programme is confined to US devices and stated safeguards are in place to protect sensitive information.

The news agency noted Meta acknowledged in a question-and-answer document provided to employees MCI will capture the contents of any emails or direct messages sent to US personnel, regardless of the sender’s ⁠location.

Meta spokesperson Dave Arnold told Reuters the company notified non-US employees the tool was running on the machines of US-based colleagues they might correspond with, describing the step as one of transparency.

A representative for Meta told Mobile World Live: “We’ve been clear that this tool is for US-based personnel only, and in the interest of transparency, we notified non-US employees that it was deployed on the computers of US colleagues they may email or chat with in the normal course of business.”

“We carefully considered and mitigated potential privacy risks in both the development and deployment of this tool, and we are committed to complying with applicable laws and regulations.” 

New regulatory exposure
Reuters stated the disclosure introduces new regulatory exposure in Europe, where technology companies are already fighting a series of heated legal battles over data collection.

Under the EU’s GDPR rules, the news site explained companies must establish a clear legal basis for processing personal data, disclose what is being collected and satisfy strict conditions around sensitive categories of information.

Kleanthi Sardeli, a legal expert at privacy advocacy group NOYB, told the news site even limited or incidental capture of EU employee data could put Meta in breach of GDPR rules.

A key question, she said, is whether data originally gathered for work communications can lawfully be repurposed to train an AI model.

The post Meta tracking tool raises EU GDPR concerns appeared first on Mobile World Live.

The European Union (EU) is pressing for deeper talks with the US administration over advanced AI models, and at the heart of the conversation is Anthropic’s Mythos.

There are growing concerns among governments over the security implications of Mythos, which Anthropic released to private companies in April.

Its release triggered an immediate wave of concern when it surfaced the model could identify tens of thousands of software vulnerabilities at a scale no previous system had demonstrated.

The AI player introduced its Mythos model on 7 April, under the auspices of Project Glasswing, to a limited number of technology companies including Amazon Web Services, Apple, Nvidia and Google.

Anthropic expects to bring Mythos-class models to all customers in the coming weeks.

Bloomberg previously reported the EU made limited progress in securing access to details of vulnerabilities Anthropic’s Mythos AI model could reveal.

European Commission spokesperson Thomas Regnier told Mobile World Live (MWL) the agency has had several meetings with Anthropic to understand the capability of the model, its implications for the cybersecurity of the EU and Anthropic’s plan around Project Glasswing.

“We will keep discussing with the company the cyber capabilities and risks of its latest model,” he stated.

CNBC reported Anthropic has yet to grant the EU, its AI office or any government organisations outside of the US, aside from the UK’s AI Security Institute, preview access to Mythos.

Since August 2025, the European Commission’s AI Office has held regular technical meetings with Anthropic tied to the General-Purpose AI Code of Practice, to which the company is a signatory.

A spokesperson for the EC noted Mythos is not a one-off as a “new wave of powerful models are coming to the market”.

The EC stated parallel progress is being made towards releasing OpenAI’s GPT-5.5-Cyber to trusted EU entities.

The EC spokesperson told MWL it is intensifying discussions with the US, “particularly on the most advanced AI models, including those with cyber capabilities”.

“Cybersecurity is a shared priority and we have agreed to mutually recognise our respective standards in this area,” the spokesperson stated.  “On EU side, we are also stepping up our cyber defences through targeted investments in AI and supercomputing.”

The post EU pushes for access to Anthropic model as fears grow appeared first on Mobile World Live.

In a groundbreaking study published in Nature Communications, researchers have unveiled a striking compensatory mechanism that could revolutionize the understanding and treatment of mitochondrial disorders, particularly Leigh-like encephalopathy linked to mutations in the COXFA4 gene. This research elucidates the role of a previously underappreciated mitochondrial protein, COXFA4L2, whose upregulation appears to preserve cytochrome c oxidase activity despite genetic impairments, offering new hope for patients grappling with this debilitating neurodegenerative condition.

Leigh-like encephalopathy is a devastating disorder characterized by progressive neurodegeneration arising from defects in mitochondrial respiratory chain complexes. The cytochrome c oxidase complex, also known as complex IV, plays a crucial role in cellular respiration by facilitating electron transfer to oxygen, thereby driving ATP production. Mutations in the COXFA4 gene, integral to complex IV assembly or stability, severely disrupt this process, leading to energy deficits in neurons. Until now, treatment options have been limited, largely supportive, and ineffective in halting disease progression.

The newly published research by Falabella, Lopez Calcerrada, Aref, and colleagues dives deep into mitochondrial homeostasis, focusing on how the cell compensates for COXFA4 dysfunction. They discovered that COXFA4L2, a paralogous protein sharing structural similarity with COXFA4, experiences notable upregulation in cells harboring COXFA4 mutations. This expression enhancement was not only observed in cellular models but also validated in patient-derived samples, underscoring its biological relevance.

Functionally, COXFA4L2 appears to integrate into the cytochrome c oxidase complex, partially substituting for the defective COXFA4 subunit. Biochemical analyses revealed that mitochondria expressing higher levels of COXFA4L2 maintain a residual level of complex IV activity, preserving oxidative phosphorylation capacity to a greater extent than previously believed possible under such genetic constraints. This residual activity correlates with improved cellular viability and suggests a natural resilience mechanism the cell employs in face of mitochondrial distress.

From a molecular standpoint, the study utilized cryo-electron microscopy (cryo-EM) to resolve the structural incorporation of COXFA4L2 within the complex IV superstructure. The data illuminated subtle conformational adaptations in the complex permitting COXFA4L2 substitution without significantly compromising enzymatic function. This structural insight highlights an elegant evolutionary adaptation allowing mitochondrial function to persist when canonical components are impaired.

The implications of this investigation extend beyond Leigh-like encephalopathy. By unraveling how COXFA4L2 mediates functional rescue, these findings open avenues for targeted therapies that could enhance or mimic this compensatory effect. Gene therapy approaches aiming to upregulate COXFA4L2 or small molecules designed to stabilize its incorporation within complex IV could represent transformational strategies in managing mitochondrial respiratory deficiencies.

Moreover, the research team explored regulatory pathways controlling COXFA4L2 expression, identifying transcription factors responsive to mitochondrial stress signals that drive its induction. This mechanistic understanding presents additional pharmacological targets to amplify the body’s intrinsic protective response to mitochondrial dysfunction. Future studies are poised to examine these regulatory cascades across diverse mitochondrial pathologies to assess generalizability.

Clinically, the discovery of COXFA4L2’s role raises the potential for biomarkers reflective of this compensatory response, aiding in early diagnosis and prognostic evaluation of Leigh-like encephalopathy. Quantifying COXFA4L2 levels or activity in patient biofluids could provide a minimally invasive means to monitor disease status or therapeutic efficacy in real time, enhancing personalized medicine efforts.

The epidemiological context also warrants attention. Mitochondrial disorders collectively affect millions worldwide yet remain underdiagnosed due to their complex phenotypic presentations. Insights from this study encourage renewed screening initiatives in genetically at-risk populations, particularly focusing on COXFA4 mutations where COXFA4L2 upregulation might serve as both a diagnostic and therapeutic marker.

Beyond translational and clinical perspectives, this compelling work enriches foundational mitochondrial biology. It exemplifies how gene paralogs can evolve to furnish adaptive flexibility in critical bioenergetic processes, ensuring cellular survival amidst genetic perturbations. Such plasticity is likely a widespread but underexplored phenomenon in mitochondrial function that warrants further exploration.

The interdisciplinary team combined molecular genetics, biochemistry, high-resolution imaging, and clinical neurology expertise to deliver comprehensive insights into this complex biological problem. Their integrative approach exemplifies the power of cross-field collaboration to decode sophisticated cellular phenomena with direct human health implications.

In summation, the revelation that COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy constitutes a paradigm shift. It not only expands the molecular understanding of mitochondrial disease pathogenesis but also heralds tangible pathways toward innovative treatments capable of mitigating neurodegeneration and improving patient quality of life.

As the scientific community digests these striking findings, the path forward is clear: accelerate translational research focusing on COXFA4L2, optimize therapeutic modalities harnessing its protective properties, and amplify efforts to identify patients who stand to benefit. The promise of enhancing mitochondrial resilience through leveraging endogenous compensatory pathways offers a beacon of optimism in an arena historically marked by therapeutic paucity.

The future holds exciting prospects for mitochondrial medicine, inspired and propelled by discoveries such as these. By unveiling nature’s own molecular adaptations, we edge closer to conquering diseases once deemed inexorable, reaffirming the profound potential residing within cellular biology to inform and transform clinical care on a global scale.

---

Subject of Research: Mitochondrial dysfunction and compensatory mechanisms in COXFA4-related Leigh-like encephalopathy

Article Title: COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy

Article References:
Falabella, M., Lopez Calcerrada, S., Aref, J. et al. COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73455-9

Image Credits: AI Generated

European Commission (EC) EVP Henna Virkkunen unveiled a proposal for the allocation of the 2GHz spectrum band for mobile satellite services, with the lion’s share set to be reserved for companies based in the European Union (EU).

Under the plan, the EC would allocate a third of the spectrum for government and critical communications use, with the remainder available for commercial applications including direct-to-device smartphone connectivity and IoT applications.

Virkkunen stated the segment used for critical communications and government agencies would be awarded to an operator within the EU which would be tasked with ensuring integration with IRIS2 infrastructure.

Half of the proportion available for commercial use would be reserved for providers based in the EU and the remainder open to bids from companies based anywhere.  

She noted earmarking allocations to local operators would “encourage the diversification of suppliers and incentivise” entry into the market.

The EC is planning an EU-level selection process for assignment of the spectrum to ensure regulatory consistency across the bloc and allow operators to provide cross-border services.

Licences currently active for the band were allocated on an EU-wide basis.

Critical
Virkkunen said the 2GHz band is foundational to providing “satellite and terrestrial connectivity directly to our mobile devices, ensuring that all areas in the EU, and namely those where terrestrial networks are unavailable, are equipped with voice and internet connectivity”.

Noting “large networks of low Earth orbit satellites are becoming the space version” or mobile towers, she added they also pave the way for 6G.

“In short, this band is absolutely vital for our citizens, businesses and governments alike,” she added, arguing the EC’s proposal would aid in aims to boost Europe’s competitiveness and security, along with embracing “new technological possibilities”.

Although opening the way for big name US operators including Starlink and Amazon Leo to grab allocations, the move to reserve a large proportion for EU-based entities fits with a recent push around technology sovereignty and attempts to bolster local companies.

The post EC proposes local players get bulk of MSS spectrum appeared first on Mobile World Live.